Long-Duration Progressive Supranuclear Palsy: Clinical Course and Pathological Underpinnings

Milica Jecmenica Lukic*, Gesine Respondek, the MDS-endorsed PSP study group, Carolin Kurz, Yaroslau Compta, Ellen Gelpi, Leslie W. Ferguson, Alex Rajput, Claire Troakes, John C. van Swieten, Armin Giese, Sigrun Roeber, Jochen Herms, Thomas Arzberger, Günter Höglinger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
3 Downloads (Pure)

Abstract

Objectives: To identify the clinical characteristics of the subgroup of benign progressive supranuclear palsy with particularly long disease duration; to define neuropathological determinants underlying variability in disease duration in progressive supranuclear palsy. Methods: Clinical and pathological features were compared among 186 autopsy-confirmed cases with progressive supranuclear palsy with ≥10 years and shorter survival times. Results: The 45 cases (24.2%) had a disease duration of ≥10 years. The absence of ocular motor abnormalities within the first 3 years from disease onset was the only significant independent clinical predictor of longer survival. Histopathologically, the neurodegeneration parameters in each survival group were paralleled anatomically by the distribution of neuronal cytoplasmic inclusions, whereas the tufted astrocytes displayed anatomically an opposite severity pattern. Most interestingly, we found significantly less coiled bodies in those who survive longer, in contrast to patients with less favorable course. Interpretation: A considerable proportion of patients had a more ”benign” disease course with ≥10 years survival. They had a distinct pattern and evolution of core symptoms compared to patients with short survival. The inverted anatomical patterns of astrocytic tau distribution suggest distinct implications of these cell types in trans-cellular propagation. The tempo of disease progression appeared to be determined mostly by oligodendroglial tau, where the high degree of oligodendroglial tau pathology might affect neuronal integrity and function on top of neuronal tau pathology. The relative contribution of glial tau should be further explored in cellular and animal models. ANN NEUROL 2022;92:637–649.

Original languageEnglish
Pages (from-to)637-649
Number of pages13
JournalAnnals of Neurology
Volume92
Issue number4
DOIs
Publication statusPublished - Oct 2022

Bibliographical note

Acknowledgments
We thank the patients and their families, without whose support and altruism this research would not have been possible. The project was supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198), DFG grants (HO2402/6-2, HO2402/18-1 MSAomics), the German Federal Ministry of Education and Research (BMBF, 01EK1605A HitTau), the NOMIS foundation (FTLD project), the German Center for Neurodegenerative Diseases e.V. (DZNE), VolkswagenStiftung / Lower Saxony Ministry for Science/Petermax-Müller Foundation (Niedersächsisches Vorab - Etiology and Therapy of Synucleinopathies and Tauopathies), the Ministry of Education, Science and Technological Development Republic of Serbia (project N 175090). Several author(s) of this publication are members of the European Reference Network for Rare Neurological Diseases - Project ID No 739510.

Hospital Clínic de Barcelona/IDIBAPS are supported by the CERCA programme of Generalitat de Catalunya. Open Access funding enabled and organized by Projekt DEAL.

Publisher Copyright:
© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Fingerprint

Dive into the research topics of 'Long-Duration Progressive Supranuclear Palsy: Clinical Course and Pathological Underpinnings'. Together they form a unique fingerprint.

Cite this